Vertex Pharmaceuticals Incorporated (FRA:VX1)
330.45
-2.25 (-0.68%)
At close: Sep 30, 2025
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,100 employees as of December 31, 2024. The number of employees increased by 700 or 12.96% compared to the previous year.
Employees
6,100
Change (1Y)
700
Growth (1Y)
12.96%
Revenue / Employee
€1,593,952
Profits / Employee
€507,773
Market Cap
86.39B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6,100 | 700 | 12.96% |
Dec 31, 2023 | 5,400 | 600 | 12.50% |
Dec 31, 2022 | 4,800 | 900 | 23.08% |
Dec 31, 2021 | 3,900 | 500 | 14.71% |
Dec 31, 2020 | 3,400 | 400 | 13.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Siemens Energy AG | 98,000 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
Vertex Pharmaceuticals News
- 12 days ago - Vertex Pharmaceuticals Secures Italian Reimbursement Agreement For Gene-Edited Therapy CASGEVY - Nasdaq
- 12 days ago - Vertex Pharmaceuticals (VRTX) Secures Italian Reimbursement for Gene-Edited Therapy - GuruFocus
- 12 days ago - Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy - Business Wire
- 14 days ago - This ETF Holds Stocks Insiders Want to Own - Nasdaq
- 15 days ago - 1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals - The Motley Fool
- 17 days ago - Vertex Pharmaceuticals: Buying The CF Fortress For The Journavx Optionality - Seeking Alpha
- 19 days ago - Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years - Benzinga
- 19 days ago - Evercore ISI Group Lowers Price Target for Vertex Pharmaceuticals (VRTX) | VRTX Stock News - GuruFocus